Syndax Pharmaceuticals News

Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships

TipRanksApr 26 06:15 ET

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.

PRNewswireApr 10 16:05 ET

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)

TipRanksApr 9 05:40 ET

Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)

TipRanksApr 8 19:50 ET

Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects

TipRanksApr 8 11:35 ET

Express News | Live On CNBC, StemPoint Capital CIO Michelle Ross Mentioned Syndax Pharmaceuticals, Shares Spiked Higher

Moomoo 24/7Apr 3 12:52 ET

Express News | Syndax Disclosed Completion Of Enrollment In AUGMENT-101 Pivotal Trial Cohort Of Patients With Relapsed/Refractory MNPM1 Acute Myeloid Leukemia & Expects Topline Data In Q1 2024

Moomoo 24/7Mar 28 07:03 ET

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)

TipRanksMar 27 07:00 ET

Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Syndax Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 27 06:31 ET

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Maintains $41 Price Target

HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals with a Buy and maintains $41 price target.

Analyst UpgradesMar 27 06:21 ET

Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment

Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acu

MT NewswiresMar 26 16:49 ET

Syndax Pharmaceuticals Is Maintained at Overweight by JP Morgan

Syndax Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow JonesMar 20 11:56 ET

Express News | JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $34

Moomoo 24/7Mar 20 11:46 ET

Syndax Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 52.47% JP Morgan $31 → $34 Maintains Overweight 02/28/2024 83.86% HC Wainwright & Co. → $41 Rei

BenzingaMar 20 11:45 ET

Sector Update: Health Care Stocks Rise Monday Afternoon

Health care stocks climbed Monday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each rising 0.2%. The iShares Biotechnology ETF (IBB) gained 0.2%. In corp

MT NewswiresMar 18 14:01 ET

Syndax Pharmaceuticals Welcomes New CCO Steven Closter

TipRanksMar 18 07:22 ET

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Yahoo FinanceMar 13 08:54 ET

Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year

Seeking AlphaMar 10 13:08 ET

Buy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory Milestones

TipRanksMar 5 19:45 ET

Does Syndax Pharmaceuticals (NASDAQ:SNDX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StMar 3 09:52 ET